nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—CYP3A4—Fingolimod—multiple sclerosis	0.15	0.246	CbGbCtD
Rifaximin—CYP3A4—Methylprednisolone—multiple sclerosis	0.0967	0.158	CbGbCtD
Rifaximin—CYP3A4—Triamcinolone—multiple sclerosis	0.0733	0.12	CbGbCtD
Rifaximin—CYP3A4—Mitoxantrone—multiple sclerosis	0.0706	0.116	CbGbCtD
Rifaximin—CYP3A4—Betamethasone—multiple sclerosis	0.0629	0.103	CbGbCtD
Rifaximin—CYP3A4—Prednisolone—multiple sclerosis	0.0621	0.102	CbGbCtD
Rifaximin—CYP3A4—Prednisone—multiple sclerosis	0.0586	0.0959	CbGbCtD
Rifaximin—CYP3A4—Dexamethasone—multiple sclerosis	0.0366	0.0599	CbGbCtD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00507	0.165	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00507	0.165	CbGpPWpGaD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.00289	0.0943	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—PGR—multiple sclerosis	0.00217	0.0709	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.00171	0.056	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00166	0.0541	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—VDR—multiple sclerosis	0.00152	0.0495	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.0012	0.0391	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.000982	0.0321	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000586	0.0191	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000586	0.0191	CbGpPWpGaD
Rifaximin—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000519	0.0169	CbGpPWpGaD
Rifaximin—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000499	0.00139	CcSEcCtD
Rifaximin—Urticaria—Mitoxantrone—multiple sclerosis	0.000496	0.00138	CcSEcCtD
Rifaximin—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000495	0.00138	CcSEcCtD
Rifaximin—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000493	0.00138	CcSEcCtD
Rifaximin—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000493	0.00138	CcSEcCtD
Rifaximin—Myalgia—Triamcinolone—multiple sclerosis	0.000491	0.00137	CcSEcCtD
Rifaximin—Vomiting—Azathioprine—multiple sclerosis	0.000491	0.00137	CcSEcCtD
Rifaximin—Pneumonia—Methotrexate—multiple sclerosis	0.00049	0.00137	CcSEcCtD
Rifaximin—Myalgia—Methylprednisolone—multiple sclerosis	0.00049	0.00137	CcSEcCtD
Rifaximin—Arthralgia—Methylprednisolone—multiple sclerosis	0.00049	0.00137	CcSEcCtD
Rifaximin—Infestation—Methotrexate—multiple sclerosis	0.000488	0.00136	CcSEcCtD
Rifaximin—Infestation NOS—Methotrexate—multiple sclerosis	0.000488	0.00136	CcSEcCtD
Rifaximin—Rash—Azathioprine—multiple sclerosis	0.000487	0.00136	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000487	0.00136	CcSEcCtD
Rifaximin—Dermatitis—Azathioprine—multiple sclerosis	0.000486	0.00136	CcSEcCtD
Rifaximin—Depression—Methotrexate—multiple sclerosis	0.000486	0.00136	CcSEcCtD
Rifaximin—Flushing—Prednisone—multiple sclerosis	0.000486	0.00136	CcSEcCtD
Rifaximin—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000486	0.00135	CcSEcCtD
Rifaximin—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000486	0.00135	CcSEcCtD
Rifaximin—Discomfort—Triamcinolone—multiple sclerosis	0.000485	0.00135	CcSEcCtD
Rifaximin—Discomfort—Methylprednisolone—multiple sclerosis	0.000484	0.00135	CcSEcCtD
Rifaximin—Headache—Azathioprine—multiple sclerosis	0.000484	0.00135	CcSEcCtD
Rifaximin—Dry mouth—Triamcinolone—multiple sclerosis	0.00048	0.00134	CcSEcCtD
Rifaximin—Angioedema—Betamethasone—multiple sclerosis	0.000478	0.00133	CcSEcCtD
Rifaximin—Angioedema—Dexamethasone—multiple sclerosis	0.000478	0.00133	CcSEcCtD
Rifaximin—Angiopathy—Prednisone—multiple sclerosis	0.000475	0.00132	CcSEcCtD
Rifaximin—Confusional state—Methylprednisolone—multiple sclerosis	0.000474	0.00132	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—ZNF746—multiple sclerosis	0.000473	0.0154	CbGpPWpGaD
Rifaximin—Malaise—Dexamethasone—multiple sclerosis	0.000472	0.00132	CcSEcCtD
Rifaximin—Malaise—Betamethasone—multiple sclerosis	0.000472	0.00132	CcSEcCtD
Rifaximin—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000471	0.00131	CcSEcCtD
Rifaximin—Vertigo—Dexamethasone—multiple sclerosis	0.00047	0.00131	CcSEcCtD
Rifaximin—Vertigo—Betamethasone—multiple sclerosis	0.00047	0.00131	CcSEcCtD
Rifaximin—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.00047	0.00131	CcSEcCtD
Rifaximin—Syncope—Betamethasone—multiple sclerosis	0.000469	0.00131	CcSEcCtD
Rifaximin—Syncope—Dexamethasone—multiple sclerosis	0.000469	0.00131	CcSEcCtD
Rifaximin—Infection—Triamcinolone—multiple sclerosis	0.000468	0.0013	CcSEcCtD
Rifaximin—Infection—Methylprednisolone—multiple sclerosis	0.000467	0.0013	CcSEcCtD
Rifaximin—Haematuria—Methotrexate—multiple sclerosis	0.000465	0.0013	CcSEcCtD
Rifaximin—Shock—Triamcinolone—multiple sclerosis	0.000463	0.00129	CcSEcCtD
Rifaximin—Insomnia—Prednisolone—multiple sclerosis	0.000463	0.00129	CcSEcCtD
Rifaximin—Shock—Methylprednisolone—multiple sclerosis	0.000462	0.00129	CcSEcCtD
Rifaximin—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000461	0.00128	CcSEcCtD
Rifaximin—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00046	0.00128	CcSEcCtD
Rifaximin—Loss of consciousness—Betamethasone—multiple sclerosis	0.00046	0.00128	CcSEcCtD
Rifaximin—Epistaxis—Methotrexate—multiple sclerosis	0.00046	0.00128	CcSEcCtD
Rifaximin—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00046	0.00128	CcSEcCtD
Rifaximin—Mental disorder—Prednisone—multiple sclerosis	0.000459	0.00128	CcSEcCtD
Rifaximin—Nausea—Azathioprine—multiple sclerosis	0.000459	0.00128	CcSEcCtD
Rifaximin—Skin disorder—Methylprednisolone—multiple sclerosis	0.000456	0.00127	CcSEcCtD
Rifaximin—Malnutrition—Prednisone—multiple sclerosis	0.000456	0.00127	CcSEcCtD
Rifaximin—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000455	0.00127	CcSEcCtD
Rifaximin—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000454	0.00127	CcSEcCtD
Rifaximin—Asthenia—Mitoxantrone—multiple sclerosis	0.000448	0.00125	CcSEcCtD
Rifaximin—Myalgia—Dexamethasone—multiple sclerosis	0.000446	0.00124	CcSEcCtD
Rifaximin—Myalgia—Betamethasone—multiple sclerosis	0.000446	0.00124	CcSEcCtD
Rifaximin—Discomfort—Dexamethasone—multiple sclerosis	0.00044	0.00123	CcSEcCtD
Rifaximin—Discomfort—Betamethasone—multiple sclerosis	0.00044	0.00123	CcSEcCtD
Rifaximin—Haemoglobin—Methotrexate—multiple sclerosis	0.00044	0.00123	CcSEcCtD
Rifaximin—Hypotension—Methylprednisolone—multiple sclerosis	0.000439	0.00122	CcSEcCtD
Rifaximin—Pain—Prednisolone—multiple sclerosis	0.000438	0.00122	CcSEcCtD
Rifaximin—Haemorrhage—Methotrexate—multiple sclerosis	0.000438	0.00122	CcSEcCtD
Rifaximin—Pharyngitis—Methotrexate—multiple sclerosis	0.000434	0.00121	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—PTBP1—multiple sclerosis	0.000432	0.0141	CbGpPWpGaD
Rifaximin—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000432	0.00121	CcSEcCtD
Rifaximin—Urethral disorder—Methotrexate—multiple sclerosis	0.000429	0.0012	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000429	0.0012	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000428	0.00119	CcSEcCtD
Rifaximin—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000427	0.00119	CcSEcCtD
Rifaximin—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000427	0.00119	CcSEcCtD
Rifaximin—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000427	0.00119	CcSEcCtD
Rifaximin—Insomnia—Triamcinolone—multiple sclerosis	0.000426	0.00119	CcSEcCtD
Rifaximin—Insomnia—Methylprednisolone—multiple sclerosis	0.000425	0.00118	CcSEcCtD
Rifaximin—Infection—Betamethasone—multiple sclerosis	0.000424	0.00118	CcSEcCtD
Rifaximin—Infection—Dexamethasone—multiple sclerosis	0.000424	0.00118	CcSEcCtD
Rifaximin—Ill-defined disorder—Prednisone—multiple sclerosis	0.000423	0.00118	CcSEcCtD
Rifaximin—Feeling abnormal—Prednisolone—multiple sclerosis	0.000422	0.00118	CcSEcCtD
Rifaximin—Anaemia—Prednisone—multiple sclerosis	0.000421	0.00118	CcSEcCtD
Rifaximin—Shock—Betamethasone—multiple sclerosis	0.00042	0.00117	CcSEcCtD
Rifaximin—Shock—Dexamethasone—multiple sclerosis	0.00042	0.00117	CcSEcCtD
Rifaximin—Dyspnoea—Triamcinolone—multiple sclerosis	0.00042	0.00117	CcSEcCtD
Rifaximin—Nervous system disorder—Betamethasone—multiple sclerosis	0.000419	0.00117	CcSEcCtD
Rifaximin—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000419	0.00117	CcSEcCtD
Rifaximin—Angioedema—Prednisone—multiple sclerosis	0.000417	0.00116	CcSEcCtD
Rifaximin—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000413	0.00115	CcSEcCtD
Rifaximin—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000413	0.00115	CcSEcCtD
Rifaximin—Malaise—Prednisone—multiple sclerosis	0.000411	0.00115	CcSEcCtD
Rifaximin—Vertigo—Prednisone—multiple sclerosis	0.00041	0.00114	CcSEcCtD
Rifaximin—Syncope—Prednisone—multiple sclerosis	0.000409	0.00114	CcSEcCtD
Rifaximin—Tinnitus—Methotrexate—multiple sclerosis	0.000408	0.00114	CcSEcCtD
Rifaximin—Anorexia—Betamethasone—multiple sclerosis	0.000407	0.00114	CcSEcCtD
Rifaximin—Anorexia—Dexamethasone—multiple sclerosis	0.000407	0.00114	CcSEcCtD
Rifaximin—Urticaria—Prednisolone—multiple sclerosis	0.000407	0.00113	CcSEcCtD
Rifaximin—Fatigue—Triamcinolone—multiple sclerosis	0.000406	0.00113	CcSEcCtD
Rifaximin—Fatigue—Methylprednisolone—multiple sclerosis	0.000405	0.00113	CcSEcCtD
Rifaximin—Pain—Triamcinolone—multiple sclerosis	0.000403	0.00112	CcSEcCtD
Rifaximin—Loss of consciousness—Prednisone—multiple sclerosis	0.000401	0.00112	CcSEcCtD
Rifaximin—Hypotension—Betamethasone—multiple sclerosis	0.000399	0.00111	CcSEcCtD
Rifaximin—Hypotension—Dexamethasone—multiple sclerosis	0.000399	0.00111	CcSEcCtD
Rifaximin—Angiopathy—Methotrexate—multiple sclerosis	0.000397	0.00111	CcSEcCtD
Rifaximin—Vomiting—Mitoxantrone—multiple sclerosis	0.000397	0.00111	CcSEcCtD
Rifaximin—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000394	0.0011	CcSEcCtD
Rifaximin—Rash—Mitoxantrone—multiple sclerosis	0.000393	0.0011	CcSEcCtD
Rifaximin—Dermatitis—Mitoxantrone—multiple sclerosis	0.000393	0.0011	CcSEcCtD
Rifaximin—Headache—Mitoxantrone—multiple sclerosis	0.000391	0.00109	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000389	0.00109	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000389	0.00109	CcSEcCtD
Rifaximin—Arthralgia—Prednisone—multiple sclerosis	0.000388	0.00108	CcSEcCtD
Rifaximin—Myalgia—Prednisone—multiple sclerosis	0.000388	0.00108	CcSEcCtD
Rifaximin—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000388	0.00108	CcSEcCtD
Rifaximin—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000387	0.00108	CcSEcCtD
Rifaximin—Insomnia—Dexamethasone—multiple sclerosis	0.000386	0.00108	CcSEcCtD
Rifaximin—Insomnia—Betamethasone—multiple sclerosis	0.000386	0.00108	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000385	0.00107	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000384	0.00107	CcSEcCtD
Rifaximin—Discomfort—Prednisone—multiple sclerosis	0.000383	0.00107	CcSEcCtD
Rifaximin—Mental disorder—Methotrexate—multiple sclerosis	0.000383	0.00107	CcSEcCtD
Rifaximin—Malnutrition—Methotrexate—multiple sclerosis	0.000381	0.00106	CcSEcCtD
Rifaximin—Hypersensitivity—Prednisolone—multiple sclerosis	0.000377	0.00105	CcSEcCtD
Rifaximin—Urticaria—Triamcinolone—multiple sclerosis	0.000374	0.00104	CcSEcCtD
Rifaximin—Urticaria—Methylprednisolone—multiple sclerosis	0.000373	0.00104	CcSEcCtD
Rifaximin—Body temperature increased—Triamcinolone—multiple sclerosis	0.000372	0.00104	CcSEcCtD
Rifaximin—Anaphylactic shock—Prednisone—multiple sclerosis	0.000372	0.00104	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000372	0.0122	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000372	0.0122	CbGpPWpGaD
Rifaximin—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000371	0.00104	CcSEcCtD
Rifaximin—Decreased appetite—Dexamethasone—multiple sclerosis	0.000371	0.00104	CcSEcCtD
Rifaximin—Decreased appetite—Betamethasone—multiple sclerosis	0.000371	0.00104	CcSEcCtD
Rifaximin—Nausea—Mitoxantrone—multiple sclerosis	0.000371	0.00103	CcSEcCtD
Rifaximin—Infection—Prednisone—multiple sclerosis	0.00037	0.00103	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000369	0.00103	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000369	0.00103	CcSEcCtD
Rifaximin—Back pain—Methotrexate—multiple sclerosis	0.000369	0.00103	CcSEcCtD
Rifaximin—Fatigue—Dexamethasone—multiple sclerosis	0.000368	0.00103	CcSEcCtD
Rifaximin—Fatigue—Betamethasone—multiple sclerosis	0.000368	0.00103	CcSEcCtD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000367	0.012	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000367	0.012	CbGpPWpGaD
Rifaximin—Shock—Prednisone—multiple sclerosis	0.000366	0.00102	CcSEcCtD
Rifaximin—Pain—Betamethasone—multiple sclerosis	0.000365	0.00102	CcSEcCtD
Rifaximin—Pain—Dexamethasone—multiple sclerosis	0.000365	0.00102	CcSEcCtD
Rifaximin—Nervous system disorder—Prednisone—multiple sclerosis	0.000365	0.00102	CcSEcCtD
Rifaximin—Skin disorder—Prednisone—multiple sclerosis	0.000361	0.00101	CcSEcCtD
Rifaximin—Hyperhidrosis—Prednisone—multiple sclerosis	0.00036	0.001	CcSEcCtD
Rifaximin—Anorexia—Prednisone—multiple sclerosis	0.000355	0.000989	CcSEcCtD
Rifaximin—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000353	0.000986	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—multiple sclerosis	0.000352	0.000982	CcSEcCtD
Rifaximin—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000352	0.000982	CcSEcCtD
Rifaximin—Feeling abnormal—Betamethasone—multiple sclerosis	0.000352	0.000982	CcSEcCtD
Rifaximin—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000349	0.000974	CcSEcCtD
Rifaximin—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000349	0.000974	CcSEcCtD
Rifaximin—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000347	0.000967	CcSEcCtD
Rifaximin—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000346	0.000965	CcSEcCtD
Rifaximin—Malaise—Methotrexate—multiple sclerosis	0.000344	0.000958	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—multiple sclerosis	0.000342	0.000955	CcSEcCtD
Rifaximin—Urticaria—Dexamethasone—multiple sclerosis	0.000339	0.000946	CcSEcCtD
Rifaximin—Urticaria—Betamethasone—multiple sclerosis	0.000339	0.000946	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000339	0.000945	CcSEcCtD
Rifaximin—Dizziness—Prednisolone—multiple sclerosis	0.000339	0.000944	CcSEcCtD
Rifaximin—Asthenia—Triamcinolone—multiple sclerosis	0.000338	0.000942	CcSEcCtD
Rifaximin—Body temperature increased—Betamethasone—multiple sclerosis	0.000338	0.000942	CcSEcCtD
Rifaximin—Abdominal pain—Betamethasone—multiple sclerosis	0.000338	0.000942	CcSEcCtD
Rifaximin—Abdominal pain—Dexamethasone—multiple sclerosis	0.000338	0.000942	CcSEcCtD
Rifaximin—Body temperature increased—Dexamethasone—multiple sclerosis	0.000338	0.000942	CcSEcCtD
Rifaximin—Asthenia—Methylprednisolone—multiple sclerosis	0.000337	0.00094	CcSEcCtD
Rifaximin—Insomnia—Prednisone—multiple sclerosis	0.000336	0.000938	CcSEcCtD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000334	0.0109	CbGpPWpGaD
Rifaximin—Pruritus—Triamcinolone—multiple sclerosis	0.000333	0.000929	CcSEcCtD
Rifaximin—Cough—Methotrexate—multiple sclerosis	0.000332	0.000927	CcSEcCtD
Rifaximin—Pruritus—Methylprednisolone—multiple sclerosis	0.000332	0.000927	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—U2AF2—multiple sclerosis	0.000328	0.0107	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—HNRNPA1—multiple sclerosis	0.000328	0.0107	CbGpPWpGaD
Rifaximin—Arthralgia—Methotrexate—multiple sclerosis	0.000324	0.000905	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—multiple sclerosis	0.000324	0.000905	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—multiple sclerosis	0.000324	0.000905	CcSEcCtD
Rifaximin—Decreased appetite—Prednisone—multiple sclerosis	0.000323	0.000902	CcSEcCtD
Rifaximin—Rash—Prednisolone—multiple sclerosis	0.000323	0.0009	CcSEcCtD
Rifaximin—Dermatitis—Prednisolone—multiple sclerosis	0.000323	0.000899	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000322	0.000898	CcSEcCtD
Rifaximin—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000321	0.000896	CcSEcCtD
Rifaximin—Fatigue—Prednisone—multiple sclerosis	0.000321	0.000895	CcSEcCtD
Rifaximin—Headache—Prednisolone—multiple sclerosis	0.000321	0.000894	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—multiple sclerosis	0.00032	0.000894	CcSEcCtD
Rifaximin—Constipation—Prednisone—multiple sclerosis	0.000318	0.000887	CcSEcCtD
Rifaximin—Confusional state—Methotrexate—multiple sclerosis	0.000314	0.000874	CcSEcCtD
Rifaximin—Dizziness—Triamcinolone—multiple sclerosis	0.000311	0.000868	CcSEcCtD
Rifaximin—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000311	0.000867	CcSEcCtD
Rifaximin—Dizziness—Methylprednisolone—multiple sclerosis	0.000311	0.000866	CcSEcCtD
Rifaximin—Infection—Methotrexate—multiple sclerosis	0.000309	0.000861	CcSEcCtD
Rifaximin—Feeling abnormal—Prednisone—multiple sclerosis	0.000307	0.000855	CcSEcCtD
Rifaximin—Asthenia—Dexamethasone—multiple sclerosis	0.000307	0.000855	CcSEcCtD
Rifaximin—Asthenia—Betamethasone—multiple sclerosis	0.000307	0.000855	CcSEcCtD
Rifaximin—Nervous system disorder—Methotrexate—multiple sclerosis	0.000305	0.00085	CcSEcCtD
Rifaximin—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000304	0.000848	CcSEcCtD
Rifaximin—Nausea—Prednisolone—multiple sclerosis	0.000304	0.000848	CcSEcCtD
Rifaximin—Pruritus—Betamethasone—multiple sclerosis	0.000302	0.000843	CcSEcCtD
Rifaximin—Pruritus—Dexamethasone—multiple sclerosis	0.000302	0.000843	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—multiple sclerosis	0.000302	0.000842	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000302	0.00985	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000302	0.00985	CbGpPWpGaD
Rifaximin—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000301	0.000838	CcSEcCtD
Rifaximin—Vomiting—Triamcinolone—multiple sclerosis	0.000299	0.000835	CcSEcCtD
Rifaximin—Vomiting—Methylprednisolone—multiple sclerosis	0.000299	0.000833	CcSEcCtD
Rifaximin—Rash—Triamcinolone—multiple sclerosis	0.000297	0.000828	CcSEcCtD
Rifaximin—Dermatitis—Triamcinolone—multiple sclerosis	0.000297	0.000827	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—multiple sclerosis	0.000296	0.000827	CcSEcCtD
Rifaximin—Rash—Methylprednisolone—multiple sclerosis	0.000296	0.000826	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—PGR—multiple sclerosis	0.000296	0.00968	CbGpPWpGaD
Rifaximin—Dermatitis—Methylprednisolone—multiple sclerosis	0.000296	0.000825	CcSEcCtD
Rifaximin—Urticaria—Prednisone—multiple sclerosis	0.000296	0.000824	CcSEcCtD
Rifaximin—Headache—Triamcinolone—multiple sclerosis	0.000295	0.000823	CcSEcCtD
Rifaximin—Headache—Methylprednisolone—multiple sclerosis	0.000294	0.000821	CcSEcCtD
Rifaximin—Body temperature increased—Prednisone—multiple sclerosis	0.000294	0.00082	CcSEcCtD
Rifaximin—Abdominal pain—Prednisone—multiple sclerosis	0.000294	0.00082	CcSEcCtD
Rifaximin—Diarrhoea—Betamethasone—multiple sclerosis	0.000292	0.000815	CcSEcCtD
Rifaximin—Diarrhoea—Dexamethasone—multiple sclerosis	0.000292	0.000815	CcSEcCtD
Rifaximin—Hypotension—Methotrexate—multiple sclerosis	0.000291	0.00081	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000283	0.00079	CcSEcCtD
Rifaximin—Dizziness—Betamethasone—multiple sclerosis	0.000282	0.000788	CcSEcCtD
Rifaximin—Dizziness—Dexamethasone—multiple sclerosis	0.000282	0.000788	CcSEcCtD
Rifaximin—Insomnia—Methotrexate—multiple sclerosis	0.000281	0.000784	CcSEcCtD
Rifaximin—Nausea—Triamcinolone—multiple sclerosis	0.00028	0.00078	CcSEcCtD
Rifaximin—Nausea—Methylprednisolone—multiple sclerosis	0.000279	0.000778	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—multiple sclerosis	0.000277	0.000773	CcSEcCtD
Rifaximin—Hypersensitivity—Prednisone—multiple sclerosis	0.000274	0.000764	CcSEcCtD
Rifaximin—Vomiting—Betamethasone—multiple sclerosis	0.000272	0.000758	CcSEcCtD
Rifaximin—Vomiting—Dexamethasone—multiple sclerosis	0.000272	0.000758	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—multiple sclerosis	0.00027	0.000754	CcSEcCtD
Rifaximin—Rash—Betamethasone—multiple sclerosis	0.000269	0.000751	CcSEcCtD
Rifaximin—Rash—Dexamethasone—multiple sclerosis	0.000269	0.000751	CcSEcCtD
Rifaximin—Dermatitis—Betamethasone—multiple sclerosis	0.000269	0.000751	CcSEcCtD
Rifaximin—Dermatitis—Dexamethasone—multiple sclerosis	0.000269	0.000751	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000268	0.000749	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—multiple sclerosis	0.000268	0.000748	CcSEcCtD
Rifaximin—Headache—Betamethasone—multiple sclerosis	0.000268	0.000746	CcSEcCtD
Rifaximin—Headache—Dexamethasone—multiple sclerosis	0.000268	0.000746	CcSEcCtD
Rifaximin—Asthenia—Prednisone—multiple sclerosis	0.000267	0.000744	CcSEcCtD
Rifaximin—Pain—Methotrexate—multiple sclerosis	0.000266	0.000742	CcSEcCtD
Rifaximin—Pruritus—Prednisone—multiple sclerosis	0.000263	0.000734	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—ZFP36L1—multiple sclerosis	0.000259	0.00846	CbGpPWpGaD
Rifaximin—Feeling abnormal—Methotrexate—multiple sclerosis	0.000256	0.000715	CcSEcCtD
Rifaximin—Diarrhoea—Prednisone—multiple sclerosis	0.000255	0.00071	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000254	0.000709	CcSEcCtD
Rifaximin—Nausea—Betamethasone—multiple sclerosis	0.000254	0.000708	CcSEcCtD
Rifaximin—Nausea—Dexamethasone—multiple sclerosis	0.000254	0.000708	CcSEcCtD
Rifaximin—Urticaria—Methotrexate—multiple sclerosis	0.000247	0.000689	CcSEcCtD
Rifaximin—Dizziness—Prednisone—multiple sclerosis	0.000246	0.000686	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—multiple sclerosis	0.000246	0.000685	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—multiple sclerosis	0.000246	0.000685	CcSEcCtD
Rifaximin—Vomiting—Prednisone—multiple sclerosis	0.000237	0.00066	CcSEcCtD
Rifaximin—Rash—Prednisone—multiple sclerosis	0.000235	0.000654	CcSEcCtD
Rifaximin—Dermatitis—Prednisone—multiple sclerosis	0.000234	0.000654	CcSEcCtD
Rifaximin—Headache—Prednisone—multiple sclerosis	0.000233	0.00065	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—multiple sclerosis	0.000229	0.000639	CcSEcCtD
Rifaximin—Asthenia—Methotrexate—multiple sclerosis	0.000223	0.000622	CcSEcCtD
Rifaximin—Nausea—Prednisone—multiple sclerosis	0.000221	0.000616	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—multiple sclerosis	0.00022	0.000613	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—multiple sclerosis	0.000213	0.000593	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—VDR—multiple sclerosis	0.000207	0.00676	CbGpPWpGaD
Rifaximin—Dizziness—Methotrexate—multiple sclerosis	0.000206	0.000573	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—PABPC1—multiple sclerosis	0.000201	0.00656	CbGpPWpGaD
Rifaximin—Vomiting—Methotrexate—multiple sclerosis	0.000198	0.000551	CcSEcCtD
Rifaximin—Rash—Methotrexate—multiple sclerosis	0.000196	0.000547	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—multiple sclerosis	0.000196	0.000546	CcSEcCtD
Rifaximin—Headache—Methotrexate—multiple sclerosis	0.000195	0.000543	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000192	0.00626	CbGpPWpGaD
Rifaximin—Nausea—Methotrexate—multiple sclerosis	0.000185	0.000515	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—RPL5—multiple sclerosis	0.000181	0.00592	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.00016	0.00523	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.00016	0.00523	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000158	0.00516	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000158	0.00516	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PGR—multiple sclerosis	0.000143	0.00466	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—VDR—multiple sclerosis	9.96e-05	0.00326	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.37e-05	0.00273	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—MYC—multiple sclerosis	8.23e-05	0.00269	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.78e-05	0.00222	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MYC—multiple sclerosis	3.96e-05	0.00129	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SRM—multiple sclerosis	3.89e-05	0.00127	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.6e-05	0.00118	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.74e-05	0.000895	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.74e-05	0.000895	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.51e-05	0.000818	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.08e-05	0.000678	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.19e-05	0.00039	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOE—multiple sclerosis	7.17e-06	0.000234	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—POMC—multiple sclerosis	6.16e-06	0.000201	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALB—multiple sclerosis	5.62e-06	0.000184	CbGpPWpGaD
